Table 1 Demographics and patient comorbidities. N total = 1289. BMI: body mass index, COPD: chronic obstructive pulmonary disease, MI: myocardial infarction, ESRD: end-stage renal disease, CAD: coronary artery disease, CKD: chronic kidney disease, DVT: deep venous thrombosis, PE: pulmonary embolism, DOAC: direct oral anticoagulant. White refers to non-white, non-Hispanic

From: Blood type and outcomes in patients with COVID-19

Factor Level Blood type A Blood type B Blood type AB Blood type O P value
N   440 201 61 587  
Age, mean (SD)   56.9 (18.6) 57.6 (18.1) 57.1 (19.9) 54.8 (18.1) 0.14
BMI, mean (SD)   30.8 (6.5) 30.6 (6.7) 29.4 (5.4) 32.0 (14.9) 0.32
Rhesus positive   392 (89.1%) 183 (91.0%) 53 (86.9%) 533 (90.8%) 0.63
Female sex   299 (68.0%) 136 (67.7%) 33 (54.1%) 404 (68.8%) 0.14
Language (primary) English 328 (74.5%) 149 (74.1%) 54 (88.5%) 382 (65.1%) <0.001
Spanish 88 (20.0%) 36 (17.9%) 4 (6.6%) 180 (30.7%)  
Other 24 (5.5%) 16 (8.0%) 3 (4.9%) 25 (4.3%)  
Race White 221 (50.2%) 80 (39.8%) 28 (45.9%) 224 (38.2%) 0.008
Black 84 (19.1%) 49 (24.4%) 15 (24.6%) 114 (19.4%)  
Hispanic 52 (11.8%) 25 (12.4%) 4 (6.6%) 103 (17.5%)  
Other 77 (17.5%) 41 (20.4%) 13 (21.3%) 128 (21.8%)  
Not Reported 6 (1.4%) 6 (3.0%) 1 (1.6%) 18 (3.1%)  
Hypertension   256 (58.2%) 124 (61.7%) 42 (68.9%) 341 (58.1%) 0.34
Smoker   97 (22.0%) 39 (19.4%) 15 (24.6%) 117 (19.9%) 0.69
Hyperlipidemia   251 (57.0%) 105 (52.2%) 35 (57.4%) 323 (55.0%) 0.70
COPD   55 (12.5%) 26 (12.9%) 9 (14.8%) 72 (12.3%) 0.95
Diabetes mellitus   150 (34.1%) 66 (32.8%) 25 (41.0%) 197 (33.6%) 0.68
Cancer diagnosis   131 (29.8%) 57 (28.4%) 19 (31.1%) 161 (27.4%) 0.83
Cirrhosis   14 (3.2%) 9 (4.5%) 1 (1.6%) 21 (3.6%) 0.72
Asthma   124 (28.2%) 46 (22.9%) 14 (23.0%) 163 (27.8%) 0.44
History of stroke   50 (11.4%) 30 (14.9%) 10 (16.4%) 71 (12.1%) 0.47
ESRD   17 (3.9%) 13 (6.5%) 5 (8.2%) 30 (5.1%) 0.33
CAD   171 (38.9%) 71 (35.3%) 30 (49.2%) 231 (39.4%) 0.28
CKD   74 (16.8%) 41 (20.4%) 12 (19.7%) 111 (18.9%) 0.70
Dysrhythmia   199 (45.2%) 95 (47.3%) 34 (55.7%) 274 (46.7%) 0.49
Congestive heart failure   71 (16.1%) 41 (20.4%) 13 (21.3%) 107 (18.2%) 0.51
History DVT   39 (8.9%) 14 (7.0%) 6 (9.8%) 43 (7.3%) 0.71
History PE   26 (5.9%) 10 (5.0%) 4 (6.6%) 24 (4.1%) 0.55
Aspirin   66 (15.0%) 45 (22.4%) 16 (26.2%) 96 (16.4%) 0.029
Warfarin   14 (3.2%) 7 (3.5%) 1 (1.6%) 20 (3.4%) 0.90
Statin use   132 (30.0%) 64 (31.8%) 25 (41.0%) 141 (24.0%) 0.007
Calcium channel blocker   56 (12.7%) 29 (14.4%) 5 (8.2%) 76 (12.9%) 0.65
Thiazide diuretic   36 (8.2%) 14 (7.0%) 4 (6.6%) 46 (7.8%) 0.94
ACE inhibitor   59 (13.4%) 32 (15.9%) 7 (11.5%) 81 (13.8%) 0.78
ARB   32 (7.3%) 19 (9.5%) 6 (9.8%) 50 (8.5%) 0.76
Beta blocker   97 (22.0%) 51 (25.4%) 14 (23.0%) 124 (21.1%) 0.66
DOAC   31 (7.0%) 12 (6.0%) 6 (9.8%) 23 (3.9%) 0.071
p2y12 inhibitor   11 (2.5%) 11 (5.5%) 4 (6.6%) 9 (1.5%) 0.006